Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/4/238 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849714010749927424 |
|---|---|
| author | Andrée-Anne Pelland Mathilde Dumas Émilie Lemieux-Blanchard Richard LeBlanc Julie Côté Jean-Samuel Boudreault Dominic Duquette Rayan Kaedbey Marc Lalancette Frédéric Larose Anna Nikonova Michel Pavic April Shamy Jean Roy Michael Sebag Sabrina Trudel Jean-Sébastien Claveau |
| author_facet | Andrée-Anne Pelland Mathilde Dumas Émilie Lemieux-Blanchard Richard LeBlanc Julie Côté Jean-Samuel Boudreault Dominic Duquette Rayan Kaedbey Marc Lalancette Frédéric Larose Anna Nikonova Michel Pavic April Shamy Jean Roy Michael Sebag Sabrina Trudel Jean-Sébastien Claveau |
| author_sort | Andrée-Anne Pelland |
| collection | DOAJ |
| description | In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits in patients with heavily treated myeloma. However, complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections complicate their administration, particularly in remote centers. This review discusses the key requirements for delivering TCEs therapies, focusing on outpatient delivery. We also outline the primary acute and chronic complications of TCE therapy and their management. |
| format | Article |
| id | doaj-art-4c76ab4e0be840e3ba1aac8204a01ebe |
| institution | DOAJ |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-4c76ab4e0be840e3ba1aac8204a01ebe2025-08-20T03:13:49ZengMDPI AGCurrent Oncology1198-00521718-77292025-04-0132423810.3390/curroncol32040238Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple MyelomaAndrée-Anne Pelland0Mathilde Dumas1Émilie Lemieux-Blanchard2Richard LeBlanc3Julie Côté4Jean-Samuel Boudreault5Dominic Duquette6Rayan Kaedbey7Marc Lalancette8Frédéric Larose9Anna Nikonova10Michel Pavic11April Shamy12Jean Roy13Michael Sebag14Sabrina Trudel15Jean-Sébastien Claveau16BC Cancer, Vancouver, BC V5Z 4E6, CanadaHôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, CanadaCentre Hospitalier de l’Université de Montréal (CHUM), Montréal, QC H2X 3E4, CanadaHôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, CanadaCentre Hospitalier Universitaire de Québec (CHU), Québec, QC G1V 0E8, CanadaHôpital du Sacré-Cœur de Montréal, Montréal, QC H4J 1C5, CanadaCentre Hospitalier Universitaire de Québec (CHU), Québec, QC G1V 0E8, CanadaJewish General Hospital, Montréal, QC H3T 1E2, CanadaCentre Hospitalier Universitaire de Québec (CHU), Québec, QC G1V 0E8, CanadaHôpital Hôtel-Dieu de Lévis, Lévis, QC G6V 3Z1, CanadaMcGill University Health Center (CUSM), Montréal, QC H3A 0G4, CanadaCentre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC J1H 5H3, CanadaJewish General Hospital, Montréal, QC H3T 1E2, CanadaHôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, CanadaMcGill University Health Center (CUSM), Montréal, QC H3A 0G4, CanadaHôpital Charles-Le Moyne, Greenfield Park, QC J4V 2H1, CanadaHôpital Maisonneuve-Rosemont, Montréal, QC H1T 2M4, CanadaIn the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma. T-cell engagers are associated with sustained efficacy and progression-free survival benefits in patients with heavily treated myeloma. However, complications such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections complicate their administration, particularly in remote centers. This review discusses the key requirements for delivering TCEs therapies, focusing on outpatient delivery. We also outline the primary acute and chronic complications of TCE therapy and their management.https://www.mdpi.com/1718-7729/32/4/238bispecific antibodiesmultiple myelomatargeted immunotherapytoxicity |
| spellingShingle | Andrée-Anne Pelland Mathilde Dumas Émilie Lemieux-Blanchard Richard LeBlanc Julie Côté Jean-Samuel Boudreault Dominic Duquette Rayan Kaedbey Marc Lalancette Frédéric Larose Anna Nikonova Michel Pavic April Shamy Jean Roy Michael Sebag Sabrina Trudel Jean-Sébastien Claveau Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma Current Oncology bispecific antibodies multiple myeloma targeted immunotherapy toxicity |
| title | Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma |
| title_full | Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma |
| title_fullStr | Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma |
| title_full_unstemmed | Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma |
| title_short | Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma |
| title_sort | perspectives on outpatient delivery of bispecific t cell engager therapies for multiple myeloma |
| topic | bispecific antibodies multiple myeloma targeted immunotherapy toxicity |
| url | https://www.mdpi.com/1718-7729/32/4/238 |
| work_keys_str_mv | AT andreeannepelland perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT mathildedumas perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT emilielemieuxblanchard perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT richardleblanc perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT juliecote perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT jeansamuelboudreault perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT dominicduquette perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT rayankaedbey perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT marclalancette perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT fredericlarose perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT annanikonova perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT michelpavic perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT aprilshamy perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT jeanroy perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT michaelsebag perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT sabrinatrudel perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma AT jeansebastienclaveau perspectivesonoutpatientdeliveryofbispecifictcellengagertherapiesformultiplemyeloma |